This low rate of ROS1 testing may be due to the low prevalence of ROS1 rearrangements in patients with NSCLC that could discourage its determination in some centers, also conditioned by limited diagnostic and/or sampling resources [1, 6, 15]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.